Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Israeli Supreme Court Directs Sun Pharma To Extend Tender Offer Deadline For Taro

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Sun Pharmaceutical has extended the last date of its tender offer for purchase of outstanding ordinary shares of Taro to Oct. 3, from the previously fixed date of Sept. 3. Sun had to extend the last date to comply with an order by the Supreme Court of Israel temporarily prohibiting the closing of the offer. The tender offer will be valid until the new date unless further extended or earlier terminated

You may also be interested in...



Taro’s Merger Proposal At $15 A Share “Outrageous,” Sun Says; Extends Offer Deadline

MUMBAI - The war of words between Sun Pharmaceutical and Israeli drug maker Taro has intensified as the two companies exchange proposals and counter-proposals for a merger as directed by Israel's Supreme Court

Taro’s Merger Proposal At $15 A Share “Outrageous,” Sun Says; Extends Offer Deadline

MUMBAI - The war of words between Sun Pharmaceutical and Israeli drug maker Taro has intensified as the two companies exchange proposals and counter-proposals for a merger as directed by Israel's Supreme Court

India’s Sun Pharma Hunts For Bargains Amidst Financial Crisis

NEW DELHI - India's Sun Pharmaceutical reported a 135 percent jump in second-quarter net profit as it said it was eyeing more acquisition possibilities with the global financial crisis making valuations of generic companies more attractive

Related Content

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel